Low-dose methotrexate in sickle-cell disease: a pilot study with rationale borrowed from rheumatoid arthritis

@inproceedings{Brandalise2017LowdoseMI,
  title={Low-dose methotrexate in sickle-cell disease: a pilot study with rationale borrowed from rheumatoid arthritis},
  author={S{\'i}lvia Regina Brandalise and Rosemary Assis and Angelo Brunelli Albertoni Laranjeira and Jos{\'e} Andr{\'e}s Yunes and Pedro Otavio de Campos-Lima},
  booktitle={Experimental hematology & oncology},
  year={2017}
}
BACKGROUND Inflammation is a major feature of sickle cell disease (SCD). Low-dose methotrexate (MTX) has long been used in chronic inflammatory diseases. This pilot study examined the MTX effect on acute vaso-occlusive pain crises (VOC) in SCD patients. METHODS Fourteen adults on hydroxyurea with severe and refractory VOC received one intramuscular injection of 10 mg of MTX per week for 12 weeks. A single weekly dose of 5 mg of leucovorin was administered orally 48 h after each MTX injection… CONTINUE READING